Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul;141(1):72-7.
doi: 10.1016/j.jss.2007.03.053.

Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells

Affiliations

Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells

Joel Baumgartner et al. J Surg Res. 2007 Jul.

Abstract

Background: The immune response to melanoma is rarely curative, suggesting the emergence of immunosuppression. FOXP3-expressing regulatory T cells (T(reg) cells) function to suppress immune responses. The objective of this study was to determine if melanoma evades immune surveillance, in part, by inducing T(reg) cells.

Material and methods: Peripheral blood mononuclear cells (PBMCs) were isolated and exposed to melanoma-conditioned media (MCM) or control media for 1 week. The induction of T(reg) cells in these PBMCs was determined by measuring the proportion of CD25(+)FOXP3(+) T cells in all CD4(+) T cells by flow cytometry. FOXP3 expression was determined by mean fluorescence intensity (MFI) and Western blot. Supernatant cytokines were determined by ELISA.

Results: Normal PBMCs exposed to MCM revealed higher proportions of T(reg) cells than those exposed to control media after 6 days (3.4% versus 1.3%, respectively, P < 0.02). The expression of FOXP3 in T(reg) cells from PBMCs exposed to MCM increased over time by MFI and Western blot but was not significantly different than those exposed to control media. The level of IL-10 and TGF-beta in supernatants after 6 days growth was higher in MCM than control media, but this did not reach statistical significance.

Conclusion: Exposure of PBMCs to melanoma results in induction of FOXP3(+) T(reg) cells.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Gating strategy used for CD4+CD25+FOXP3+ Treg cells. Representative examples of flow cytometry plots and gating strategies of Treg cells from PBMCs grown in control media and MCM. Treg cells were those in the CD25+/FOXP3+ double-positive quadrant after gating for live lymphocytes and CD3+/CD4+ T cells, respectively. The quadrant labels showed the proportion of single or double-positive cells.
FIG. 2
FIG. 2
Proportion of Treg cells from normal PBMCs in MCM versus control media (n = 5). (A) Representative graph of the percentage of CD25+/FOXP3+ Treg cells in control media versus MCM over time. (B) There was a significantly higher percentage of Treg cells in MCM versus control after six days (3.4% v. 1.3%, respectively, *P < 0.02). Graph represents mean values ± SEM of the percentage of CD25+FOXP3+ Treg cells in CD3+CD4+ T cells from PBMCs grown in control media versus MCM after six days.
FIG. 2
FIG. 2
Proportion of Treg cells from normal PBMCs in MCM versus control media (n = 5). (A) Representative graph of the percentage of CD25+/FOXP3+ Treg cells in control media versus MCM over time. (B) There was a significantly higher percentage of Treg cells in MCM versus control after six days (3.4% v. 1.3%, respectively, *P < 0.02). Graph represents mean values ± SEM of the percentage of CD25+FOXP3+ Treg cells in CD3+CD4+ T cells from PBMCs grown in control media versus MCM after six days.
FIG. 3
FIG. 3
MCM increases expression of FOXP3 with time. Typical Western blot analysis showed increasing amounts of FOXP3 expression in PBMCs over time cultured in MCM. Lanes were loaded with equal volume of cell lysate and probed for GAPDH as loading controls.
FIG. 4
FIG. 4
Cytokine levels in control media versus MCM after six days growth (n = 6). Graphs represent mean values ± SEM of levels of TGF-β and IL-10 as determined by ELISA. (A) There was an increased level of TGF-β in supernatants from PBMCs grown in MCM versus control media after six days (3410 pg/ml and 2862 pg/ml, respectively, P = 0.70), but this did not reach statistical significance. (B) Concurrently, there was no significant difference in the level of IL-10 in MCM v. control media after six days growth (114 pg/ml and 49 pg/ml, respectively, P = 0.37).
FIG. 4
FIG. 4
Cytokine levels in control media versus MCM after six days growth (n = 6). Graphs represent mean values ± SEM of levels of TGF-β and IL-10 as determined by ELISA. (A) There was an increased level of TGF-β in supernatants from PBMCs grown in MCM versus control media after six days (3410 pg/ml and 2862 pg/ml, respectively, P = 0.70), but this did not reach statistical significance. (B) Concurrently, there was no significant difference in the level of IL-10 in MCM v. control media after six days growth (114 pg/ml and 49 pg/ml, respectively, P = 0.37).

References

    1. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Annals of surgery. 1991;214:491–499. discussion 499–501. - PMC - PubMed
    1. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18:3782–3793. - PubMed
    1. Saleh F, Renno W, Klepacek I, Ibrahim G, Dashti H, Asfar S, Behbehani A, Al-Sayer H, Dashti A. Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine. Current pharmaceutical design. 2005;11:3531–3543. - PubMed
    1. Jack A, Boyes C, Aydin N, Alam K, Wallack M. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surgical oncology. 2006;15:13–24. - PubMed
    1. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. Jama. 1986;256:3117–3124. - PubMed

Publication types

MeSH terms